Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has issued a patent by Japan’s Patent Office
The patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical stage CAR NK asset CHM 1301.
The patent has been granted under patent number JP 7,085,990, entitled “Chimeric antigen receptors containing a chlorotoxin domain.”
Chimeric holds the exclusive worldwide license to develop and commercialize JP 7,085,990 and related patent applications filed in other global territories.
We are delighted to have patent protection granted for CLTX CAR therapies in Japan, the third largest pharmaceutical market in the world,” Chimeric’s CEO and Managing Director, Jennifer Chow, said.
“The granting of this key Japan patent continues to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”
Chimeric Therapeutics is a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.
The company believes that cellular therapies have the promise to cure cancer, not just delay disease progression. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.
CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial.
A second CLTX CAR T phase 1 clinical trial is planned to begin in metastatic melanoma with future expansion to additional solid tumours.
CHM 2101 (CDH17 CAR T) is a novel, third generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer.
CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.
CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.
